Fibroblast Growth Factor 23-Mediated Bone Disease.

Endocrinol Metab Clin North Am

Division of Endocrinology, Diabetes and Metabolism, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address:

Published: March 2017

AI Article Synopsis

  • - FGF23 is a key player in managing phosphate and vitamin D levels in the body, and imbalances in its production can lead to various bone diseases.
  • - The article focuses on the FGF23-α-Klotho signaling pathway, providing an overview of recent advancements in understanding how FGF23 is regulated and how it functions.
  • - It also discusses the health issues connected to either too much or too little FGF23, outlining the disorders that arise from these imbalances.

Article Abstract

Fibroblast growth factor 23 (FGF23) is an important regulator of phosphate and vitamin D metabolism and its excessive or insufficient production leads to a wide variety of skeletal disorders. This article reviews the FGF23-α-Klotho signaling pathway, highlighting the latest developments in FGF23 regulation and action, and describes the disorders associated with FGF23 excess or deficiency.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ecl.2016.09.013DOI Listing

Publication Analysis

Top Keywords

fibroblast growth
8
growth factor
8
factor 23-mediated
4
23-mediated bone
4
bone disease
4
disease fibroblast
4
factor fgf23
4
fgf23 regulator
4
regulator phosphate
4
phosphate vitamin
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!